Pancreatic Cancer Research

ResearcherEmory UniversityNo recent work listed

Christina Sing-Ying Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5922-5392; OpenAlex author ID A5006154627, A5029706475. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: 2 papers

Papers 11

  1. Survival and Prognostic Factors in Patients With Pancreatic Colloid Carcinoma Compared With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002227↗
  2. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. Co-author DOI 10.5306/wjco.v14.i8.285↗
  3. In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. Co-author DOI 10.1016/j.jgo.2019.10.012↗
  4. Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001584↗
  5. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Co-author DOI 10.1002/cncr.31787↗
  6. Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Co-author DOI 10.1634/theoncologist.2017-0487↗
  7. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1038/mt.2016.66↗
  8. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1732↗
  9. Immunological predictors of overall survival in treatment naïve metastatic pancreatic cancer patients Co-author DOI 10.1186/2051-1426-3-s2-p85↗
  10. Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study. Co-author PMID 25276262↗
  11. Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Co-author DOI 10.1097/mpa.0b013e318279b87f↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bassel F. El‐Rayes · 6 shared papers, 2016–2023 · strength 0.58
  2. Olatunji Boladale Alese · 5 shared papers, 2018–2023 · strength 0.54
  3. Walid Labib Shaib · 5 shared papers, 2018–2023 · strength 0.54
  4. Mehmet Akce · 4 shared papers, 2019–2023 · strength 0.46
  5. Tanios Bekaii‐Saab · 5 shared papers, 2013–2023 · strength 0.34
  6. Daniel H. Ahn · 4 shared papers, 2015–2023 · strength 0.30
  7. Juan Manuel Sarmiento · 3 shared papers, 2018–2020 · strength 0.26
  8. Shishir Kumar Maithel · 3 shared papers, 2018–2020 · strength 0.26
  9. Pretesh R Patel · 2 shared papers, 2019–2020 · strength 0.19
  10. Lana E. Khalil · 1 shared paper, 2023 · strength 0.17
  11. Michelle Dian Reid · 1 shared paper, 2023 · strength 0.17
  12. Sujata R. Kane · 2 shared papers, 2018–2019 · strength 0.17
  13. Mitesh J. Borad · 1 shared paper, 2023 · strength 0.16
  14. Michael Scott Rutenberg · 1 shared paper, 2023 · strength 0.16
  15. John Andrew Stauffer · 1 shared paper, 2023 · strength 0.16
  16. Ahmed Elhariri · 1 shared paper, 2023 · strength 0.16
  17. Mohamad Bassam Sonbol · 1 shared paper, 2023 · strength 0.16
  18. Jason Scott Starr · 1 shared paper, 2023 · strength 0.16
  19. Hani M. Babiker · 1 shared paper, 2023 · strength 0.16
  20. Umair Majeed · 1 shared paper, 2023 · strength 0.16
  21. Matthew R. Farren · 3 shared papers, 2015–2016 · strength 0.14
  22. Thomas A. Mace · 3 shared papers, 2015–2016 · strength 0.14
  23. Gregory B. Lesinski · 3 shared papers, 2015–2016 · strength 0.14
  24. Anne M. Noonan · 3 shared papers, 2015–2016 · strength 0.14
  25. Astrid Belalcazar · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.